

# Jack D Bui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6857050/publications.pdf>

Version: 2024-02-01

52  
papers

4,147  
citations

186265  
28  
h-index

182427  
51  
g-index

53  
all docs

53  
docs citations

53  
times ranked

7252  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. <i>Nature Biomedical Engineering</i> , 2022, 6, 882-897.	22.5	41
2	AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2646-2656.	7.0	8
3	Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. <i>Nature Cell Biology</i> , 2022, 24, 954-967.	10.3	35
4	Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. <i>Nature Communications</i> , 2021, 12, 1999.	12.8	140
5	Elongated neutrophil-derived structures are blood-borne microparticles formed by rolling neutrophils during sepsis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	29
6	Machine Learning of Discriminative Gate Locations for Clinical Diagnosis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 296-307.	1.5	8
7	Evaluation of IL-17D in Host Immunity to Group A <i>Streptococcus</i> Infection. <i>Journal of Immunology</i> , 2020, 205, 3122-3129.	0.8	5
8	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	28.9	691
9	Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. <i>Science Immunology</i> , 2020, 5, .	11.9	127
10	Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor. <i>Cancer Research</i> , 2019, 79, 1996-2008.	0.9	62
11	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. <i>Immunity</i> , 2019, 51, 1059-1073.e9.	14.3	229
12	Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas. <i>Oncot Immunology</i> , 2019, 8, e1404212.	4.6	4
13	Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance. <i>Journal of Immunology</i> , 2018, 200, 4012-4023.	0.8	44
14	Mechanisms regulating immune surveillance of cellular stress in cancer. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 225-240.	5.4	22
15	Innate sensing of cancer's non-immunologic hallmarks. <i>Current Opinion in Immunology</i> , 2018, 50, 1-8.	5.5	9
16	Siglec-7 engagement by GBS Î²-protein suppresses pyroptotic cell death of natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10410-10415.	7.1	38
17	Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection. <i>Scientific Reports</i> , 2018, 8, 13670.	3.3	29
18	Survival of syngeneic and allogeneic iPSC-derived neural precursors after spinal grafting in minipigs. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	42

#	ARTICLE	IF	CITATIONS
19	Cell-cell fusion as a mechanism of DNA exchange in cancer. <i>Oncotarget</i> , 2018, 9, 6156-6173.	1.8	37
20	Neutrophils form elongated shearâ€derived particles (SDP) via shedding tethers and slings. <i>FASEB Journal</i> , 2018, 32, 574.6.	0.5	0
21	eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. <i>Cancer Research</i> , 2017, 77, 1997-2007.	0.9	57
22	Increased Foxp3 + Helios + Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 625-634.	2.0	59
23	Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis. <i>Oncolmunology</i> , 2017, 6, e1268310.	4.6	11
24	The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance. <i>Cytokine</i> , 2017, 91, 10-12.	3.2	19
25	Automated Analysis of Clinical Flow Cytometry Data. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 931-944.	1.4	7
26	The Next Frontier: Head and Neck Cancer Immunoprevention. <i>Cancer Prevention Research</i> , 2017, 10, 681-683.	1.5	9
27	Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification. <i>Journal of Clinical Investigation</i> , 2017, 127, 3609-3623.	8.2	35
28	Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. <i>Cell Reports</i> , 2016, 16, 2348-2358.	6.4	107
29	Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. <i>Cancer Immunology Research</i> , 2016, 4, 799-811.	3.4	25
30	Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition. <i>Oncotarget</i> , 2016, 7, 21527-21541.	1.8	32
31	Immunodeficiency and Autoimmune Enterocolopathy Linked to NFAT5 Haploinsufficiency. <i>Journal of Immunology</i> , 2015, 194, 2551-2560.	0.8	32
32	Drak2 is not required for tumor surveillance and suppression. <i>International Immunology</i> , 2015, 27, 161-166.	4.0	13
33	Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , 2015, 6, 41204-41215.	1.8	13
34	Hormesis in cancer immunology. <i>Oncolmunology</i> , 2014, 3, e29312.	4.6	16
35	Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14211-14216.	7.1	186
36	Tumor-expressed IL-17D recruits NK cells to reject tumors. <i>Oncolmunology</i> , 2014, 3, e954853.	4.6	18

#	ARTICLE	IF	CITATIONS
37	Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells. Cell Reports, 2014, 7, 989-998.	6.4	73
38	Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: Effect on spinally grafted human neural precursor survival. Experimental Neurology, 2013, 248, 85-99.	4.1	24
39	The nuclear factor- $\kappa$ B pathway down-regulates expression of the NKG2D ligand H60a in vitro : implications for use of nuclear factor- $\kappa$ B inhibitors in cancer therapy. Immunology, 2013, 139, 265-274.	4.4	6
40	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Journal of Experimental Medicine, 2012, 209, 1869-1882.	8.5	281
41	Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology, 2011, 133, 197-205.	4.4	2
42	Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression. Molecular Immunology, 2011, 48, 539-545.	2.2	16
43	Cancer Immunoediting of the NK Group 2D Ligand H60a. Journal of Immunology, 2011, 187, 3538-3545.	0.8	26
44	The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth. Journal of Immunology, 2010, 184, 369-378.	0.8	64
45	Cutting Edge: Down-Regulation of MHC Class I-Related Chain A on Tumor Cells by IFN- $\gamma$ -Induced MicroRNA. Journal of Immunology, 2009, 182, 39-43.	0.8	100
46	Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody. Transplantation, 2008, 86, 137-147.	1.0	70
47	Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Current Opinion in Immunology, 2007, 19, 203-208.	5.5	270
48	Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins. Cancer Research, 2006, 66, 7301-7309.	0.9	98
49	IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors. Journal of Immunology, 2006, 176, 905-913.	0.8	94
50	Interferon- $\gamma$ and Cancer Immunoediting. Immunologic Research, 2005, 32, 231-246.	2.9	123
51	A critical function for type I interferons in cancer immunoediting. Nature Immunology, 2005, 6, 722-729.	14.5	516
52	Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 852-854.	0.8	145